Innovent Biologics reports interim results

* Innovent Biologics press release [https://seekingalpha.com/pr/20212690-innovent-announces-2025-interim-results-and-business-updates] (OTCPK:IVBXF [https://seekingalpha.com/symbol/IVBXF]): Total revenue: RMB 5.95 billion, up 50.6% year-on-year
* Product revenue: RMB 5.23 billion, up 37.3% year-on-year
* Net profit: RMB 1.21 billion; EBITDA: RMB 1.41 billion
* Gross margin: 86.8%, up 2.7 percentage points year-on-year

MORE ON INNOVENT BIOLOGICS

* Neutral On Innovent Biologics: Hard To Justify Its Premium [https://seekingalpha.com/article/4796471-neutral-on-innovent-biologics-hard-to-justify-its-premium]
* How mazdutide compares against weight loss therapies from Novo Nordisk, Lilly [https://seekingalpha.com/news/4463942-how-mazdutide-compares-against-weight-loss-therapies-novo-nordisk-lilly]
* Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide [https://seekingalpha.com/news/4463539-novo-nordisk-eli-lilly-face-first-major-obesity-drug-rival-in-china-as-innovent-gains-approval-for-mazdutide]
* Historical earnings data for Innovent Biologics [https://seekingalpha.com/symbol/IVBIY/earnings]
* Financial information for Innovent Biologics [https://seekingalpha.com/symbol/IVBIY/income-statement]